BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Sep 22, 2023
Data Byte

Data comp: two IgA nephropathy therapies aiming for full approval

Two drugs received accelerated approval for IgA nephropathy: one has met its confirmatory endpoint, the other is moving ahead despite miss
BioCentury | Sep 18, 2023
Product Development

Data comp: four hypertension candidates advancing in the clinic

Idorsia’s aprocitentan under review, while Mineralys and AZ prepare for Phase III trials and Alnylam runs two more Phase II studies
BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

Drug development for heart failure is picking up, with five clinical readouts from five mechansims expected in the next year
BioCentury | May 11, 2018
Company News

La Jolla in $125M royalty financing for Giapreza

BioCentury | May 10, 2018
Financial News

La Jolla in $125M royalty financing for Giapreza

BioCentury | Mar 16, 2018
Financial News

La Jolla prices $100.3M follow-on

BioCentury | Mar 15, 2018
Financial News

La Jolla prices $100.3M follow-on

Items per page:
1 - 10 of 282